Nedaplatin
 | |
| Systematic (IUPAC) name | |
|---|---|
|
Diammine[(hydroxy-κO)acetato(2-)-κO]platinum | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | IV |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
95734-82-0  |
| ATC code | none |
| PubChem | CID 6917890 |
| UNII |
8UQ3W6JXAN |
| KEGG |
D01416 |
| Chemical data | |
| Formula | C2H8N2O3Pt |
| Molar mass | 303.17 g/mol |
| |
| (verify) | |
Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.
Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.[2]
References
- ↑ Apps, M. G., Choi, E. H. Y., Wheate, N. J. (2015). "The state-of-play and future of platinum drugs". Endocrine-related Cancer 22 (4): 219–233. doi:10.1530/ERC-15-0237. PMID 26113607.
- ↑ Johnstone, Timothy C.; Park, Ga Young; Lippard, Stephen J. (2014-01-01). "Understanding and Improving Platinum Anticancer Drugs – Phenanthriplatin". Anticancer research 34 (1): 471–476. ISSN 0250-7005. PMC 3937549. PMID 24403503.
- (Japanese) Aqupla アクプラ (PDF) Shionogi & Co. March 2007.
External links
- (Japanese) Official Shionogi & Co. Website
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.